INDEX

Note: Page numbers of article titles are in **boldface** type.

Abscess(es), at site of vaccination, 510
Adenovirus-1, canine, vaccines containing, 481
Adenovirus-2, canine, vaccines containing, 481
Adenovirus infection, canine, 481-482
Adverse events, vaccine-associated, 493-514
Alopecia, at site of vaccination, 509
American Association of Feline Practitioners, and Academy of Feline Medicine, Advisory Panel on Feline Vaccines, recommendations of, 458-461
American Veterinary Medicine Association, 499
Council on Biologic and Therapeutic agents, 440
Anaphylaxis, associated with vaccine administration, 502-504
Animal shelter(s), vaccination program for, assumptions in, 444
Darwinian approach to, 444
filtered approach to, 444
unlimited funds approach to, 444-445
Antibody titers, versus annual vaccinations, 442-443
Antigens, selection of, 443-445
in shelter environment, 443-445
vaccine, used in dogs, duration of immunity of, 488-489
Autoimmune disease, associated with vaccination, 505
Calcivirus infection, feline, 457-462
vaccination against, 462
adverse events associated with, 462-463
Canine adenovirus infection, 481-482
Canine coronaviral infection, 484-485
Canine distemper, 480-481
modified live virus vaccines against, 480
Canine distemper vaccines, recombinant, 480
Canine infectious tracheobronchitis, 482
vaccination against, 483
viruses causing, 482
Canine leptospirosis, 485-486
Canine parvoviral enteritis, 483-484
recovery from, vaccination following, 484
Canine parvovirus-2 vaccines, 483
duration of immunity conferred by, 484
recommendations for use of, 483-484
Canine vaccination, 473-492
recommendations for, revision of, 474
Cats. See also Dogs, and cats.
anaphylactic reactions in, associated with vaccines, 503
* Bordetella bronchiseptica* infection in, 467–468
dermatophytosis in, 466-467
giardiasis in, 468-469
vaccination guidelines for, 455-472
vaccination of, American Association of Feline Practitioners and Academy of Feline Medicine on, 458-461
vaccine-associated fibrosarcoma in, 447–448
vaccine-associated sarcomas in, 463, 493, 498, 509
vaccines and vaccinations for, 439-440
* Chlamydia psittaci*, 465
Chlamydiosis, clinical signs of, 465
vaccination against, 465
Coronaviral infection, canine, 484-485
vaccines for, 484

---

*Bordetella bronchiseptica*, 482
*Bordetella bronchiseptica* infection, in cats, 466-467
clinical signs of, 468
vaccine to prevent, 468
Borreliosis, Lyme, 486-487
Coronaviral infection (Continued)
challenge immunity studies of, 485
Coronaviruses, feline, 465
Cytotoxic hypersensitivity, associated with vaccine administration, 504

Dermatophytosis, in cats, 466-467
Distemper, canine, 480-481
- modified live virus vaccines against, 480
Distemper-measles vaccine, combined, 480-481
Dogs, anaphylactic reactions in, associated with vaccines, 502-503
and cats, importation of, to rabies-free areas of world, 573-583
- future directions in, 581-582
- requirements for, 574-578
- shipping regulations for, 578-581
- pre-export checklist for, 578
rabies vaccines for, 490
vaccination of, 473-492

Feline calcivirus infection, 457-462
Feline coronaviruses, 465
Feline infectious peritonitis, 465
vaccination in, benefit of, 466
Feline panleukopenia, 456
Feline parvovirus, cause of, 456
vaccination against, 456
Feline vaccination guidelines, 455-472
Feline viral rhinotracheitis, 457-462
Ferrets, anaphylactic reactions in, associated with vaccines, 503-504
Fibrosarcoma, feline vaccine-associated, 447-448

Giardia lamblia, 487
- disease caused by. See Giardiasis.
Giardiasis, 487-490
- diagnosis of, 468
- in cats, 468-469
- transmission of, 468-469
- treatment of, 468
- vaccine licensed for, 469

Hypersensitivity, Type I, associated with vaccine administration, 502-504
Type II, associated with vaccine administration, 504
Type III, associated with vaccine administration, 504-505

Immune complex-mediated hypersensitivity, associated with vaccine administration, 504-505
Immunosuppression, associated with vaccination, 505-506
Infectious peritonitis, feline, 465
vaccination in, benefit of, 466
Informed consent, veterinarian and, 518-520
International Air Transport Association
Live Animals Regulations, 579

Kennel cough, 482
Killed virus vaccine, modified-live virus versus, 443

Leptospira vaccines, 486
Leptospirosis, canine, 485-486
Leukemia virus infection, feline, transmission of, 464
vaccination against, 464-465
Local reactions, to vaccinations, 508-510
Lyme borreliosis, 486-487

Measles-distemper vaccine, combined, 480-481
Mycosporum canis, 466
vaccination against, 466-467
Modified-live virus vaccine(s), for cats, 462
for dogs, 483
versus killed virus vaccine, 443

"Naked" DNA vaccines, 450-451
National Childhood Vaccine Injury Act, 498-499
Nodules, and masses, in response to vaccination, 508
Nosodes, 452
Nucleic acid vaccines, 450-451

Pain, in response to vaccination, 508
Panleukopenia, feline, 456
Panleukopenia virus vaccine, intranasal modified-live, 505
Parvoviral enteritis, canine, 483-484
recovery from, vaccination following, 484
Parvovirus, feline, cause of, 456
vaccination against, 456-457
Pets, exposed to rabid animals, management of, 569
Rabid animals, pets exposed to, management of, 569
Rabies, as preventable disease, 558
reporting of, 463
risk of, assessment of, 559–563
transmission of, 463
type of exposure to, 559–560
Rabies-free area, WHO definition of, 573
Rabies immune globulin, 564
Rabies immunizing products, allergies and, 569
for use in human beings, 563–565
human diploid cell vaccine, 564
immunosuppression and, 568
pregnancy and, 568
purified chick embryo cell culture, 564, 565
Rabies neutralizing antibody titer test, 575
Rabies postexposure prophylaxis, 557–572
circumstances of bite and, 562
cost of, 557
decision tree, 560
for domestic animals, justification for, 570–571
in previously immunized persons, 567–568
in wild animal bites, 561–562
lack of national program concerning, 558
mortality associated with, 558
outside of United States, 567
precautions in, and contraindications to, 568–569
protocol for, 565–567
vaccination status of exposing animal and, 562–563
Rabies vaccines, administration of, statutes governing, 463
for dogs, 490
Reovirus, 482
Rhinotracheitis, feline viral, 457–462
vaccination against, 462
adverse events associated with, 462–463
Sarcoma(s), feline, soft-tissue, sites of, 526
vaccine-associated, 463, 493, 498, 509
client support in, 528
clinical evaluation procedures in, 527
diagnosis of, 526–528
physical examination findings in, 526–527
treatment of, 529–530
adjunctive, 531
client management in, 531
in microscopic metastatic disease, 530
prognosis in, 532–533
recent advances in, 525–533
supportive, 531–532
Standard of care, veterinarian and, 517–518
Swelling, benign, in response to vaccination, 508
Systemic reactions, to vaccinations, 501–508
Tracheobronchitis, canine infectious, 482
vaccination against, 483
viruses causing, 482
United States Department of Agriculture, animal vaccines and, 515–517
Center for Veterinary Biologics, 511
vaccine labels and, 541, 542, 545, 547, 551, 552–553
United States Food and Drug Administration, animal vaccines and, 515–517
United States Pharmacopeia Veterinary Practitioners’ Reporting Program, 500, 511–512
Vaccination(s), adverse events associated with, 493–494, 501–510
reporting of, 500
against feline leukemia virus infection, 464
against feline parvovirus, 456–457
annual, 440–442
antibody titers versus, 442–443
benefits of, 494–495
canine, 473–492
health maintenance prior to, 455
local reactions to, 508–510
of cats, American Association of Feline Practitioners and Academy of Feline Medicine on, 458–461
overall objectives of, 456
protocols for, for companion animals, 448
response to, environmental factors influencing, 449–450
risk(s) of, 496–498
postmarketing measurement of, 496–498
prelicensing measurement of, 496
surveillance of, 496–498
site of, abscesses at, 510
alopecia at, 509
systemic reactions to, 501–508
vaccines and, 439–583
importance of, 439
Vaccination(s) (Continued)

strategic issues concerning, 439–453
Vaccination guidelines, feline, 455–472
Vaccine(s), ability to respond to, factors negatively affecting, 455
adverse event associated with, 445–447
causes of, 447
reporting criteria for, 446–447
and vaccinations, 439–583
importance of, 439
strategic issues concerning, 439–453
animal, United States Department of Agriculture and, 515–517
United States Food and Drug Administration and, 515–517
attenuated, 445, 451
canine, 473
administration of, recommended guidelines for, 475–479
labeling of, and product inserts for, 474
canine distemper, recombinant, 480
choice of, by veterinarian, 521–522
combined distemper-measles, 480–481
contamination of, adverse events associated with, 507
core, 443
determination of, 449
efficacy measurement of, postlicensure, 495
efficacy studies of, prelicense, 494–495
federal preemption and, 517
for rabies immunization, 564–565
accidental human exposure to, 568
immunity conferred by, 480
intranasal, local reactions associated with, 510
lack efficacy of, as adverse event, 507
liability associated with, 448
modified-live virus, for cats, 462
for dogs, 483
versus killed virus vaccines, 443
multidose vials of, 448, 456
noncore, 443
over-the-counter sales of, 451–452
polyvalent, 456
annual administration of, 474
postmarketing surveillance of, 446, 498–499
potential risks of, options for reporting, 510–512
rabies, for dogs, 490
recombinant, 450–451
in veterinary medicine, 535–538
methods of producing, 536
new technology in, 536
Type I subunit, 537
Type II gene-deleted, 537–538
Type III vectored, 538
USDA classification of, 536–537
risk assessment associated with, 448–450
safety of, 445–448
selection and administration of, 456–469
veterinary, postmarketing surveillance of, 499–501
use and misuse of, potential for liability in, 515–523
Vaccine Adverse Event Reporting System, 498–499
Vaccine antigens, used in dogs, duration of immunity of, 488–489
Vaccine-associated adverse events, 493–514
Vaccine label, alternate route of administration on, 551
annual revaccination recommendations on, 550
definition of, 539–540
dose volume on, 546, 554–555
efficacy claims of, 543–546
limitations of, 548–549
minimum age of administration on, 550–551
preservatives listed on, 547
reading of, what can be and cannot be learned from reading, 539–556
reality of, understanding of regulatory process and, 540–542
revaccination interval and, 549–550
safety information on, 546
limitations of, 552–554
storage conditions on, 555
storage directions on, 547
trade name of product and, 543
true name of product and, 543
ture name on, 547–548
US Department of Agriculture and, 541, 542, 545, 547, 551, 552–553
use directions on, 546
user’s expectations of, 540
Vaccine manufacturer, veterinarians reporting adverse events to, 510–511
Vaccine virulence, residual, 506
Veterinarians, choice of vaccines by, 521–522
informed consent and, 518–520
reporting of adverse events to vaccine manufacturer, 510–511
standard of care and, 517–518

Warranty, and breach of, veterinary clients and, 520–521
World Health Organization, definition of rabies-free area of, 573